Skip to main content
NewslettersWatchlist

Vera Therapeutics Inc Cl A(VERA-Q)
NASDAQ

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Day Low41.73
Day High43.40
Open:42.67
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.
Select a category then submit the form to load news
Motley Fool
Could This Stock Be the Next Biotech Buyout?
Barchart
Markets Today: Stocks Mixed after Corporate News and Lower Bond Yields
Motley Fool
Why Vera Therapeutics Stock Soared by 22% This Week
Motley Fool
This Promising Small-Cap Biotech Stock Could Rise 70%, According to Wall Street
Motley Fool
Why Shares of Vera Therapeutics Jumped Tuesday
Motley Fool
2 Surging Healthcare Stocks With More Fuel in the Tank
Motley Fool
Why Shares of Vera Therapeutics Are Soaring Monday
PR Newswire
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Vera Therapeutics, Inc. - VERA
Business Wire
Innocoll Holdings Ltd. Appoints Kimball Hall as Chief Executive Officer
Motley Fool
Why Vera Therapeutics Stock Bolted Higher This Week
PR Newswire
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Vera Therapeutics, Inc. - VERA
Business Wire
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Vera Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm
PR Newswire
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Vera Therapeutics, Inc. - VERA
Motley Fool
These 2 Nasdaq Biotechs Are Making Big Moves Wednesday
Barchart
Pre-Market Brief: Stocks Mostly Higher Ahead of FOMC Meeting Minutes
Globe Newswire
Vera Therapeutics Provides Business Update and Reports Second Quarter 2022 Financial Results
Globe Newswire
Vera Therapeutics to Participate in the 13th Annual Wedbush PacGrow Healthcare Conference
Globe Newswire
Vera Therapeutics Completes Patient Enrollment in Phase 2b ORIGIN Clinical Trial of Atacicept for the Treatment of IgA Nephropathy
Globe Newswire
Vera Therapeutics Reports Positive Interim Phase 2 Data Showing MAU868 Has Significant BK Antiviral Activity in Kidney Transplant Patients
Globe Newswire
Vera Therapeutics to Participate in the 2022 Jefferies Healthcare Conference
Globe Newswire
Vera Therapeutics Announces New Atacicept Phase 2 Clinical Data in Two Oral Presentations at the 59th European Renal Association Congress
Globe Newswire
Vera Therapeutics Provides Business Update and Reports First Quarter 2022 Financial Results
Globe Newswire
Vera Therapeutics to Present at Upcoming Conferences in May 2022
Globe Newswire
Vera Therapeutics Announces Two Oral Presentations at the 59th European Renal Association – European Dialysis and Transplant Association Congress Featuring New Clinical Data on Atacicept in IgA Nephropathy and in Systemic Lupus Erythematosus
Globe Newswire
Vera Therapeutics Selected to Present Interim Phase 2 Data for MAU868 to Treat BK Virus in Kidney Transplant Patients as Oral Late-Breaker at the American Transplant Congress 2022
Globe Newswire
Vera Therapeutics Announces Appointment of Michael M. Morrissey, Ph.D., as Chairman of its Board of Directors
Globe Newswire
Vera Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results
Globe Newswire
Vera Therapeutics to Host BK Virus Webinar Featuring Stanley C. Jordan, M.D., World-Renowned Transplant Nephrologist and Pioneering Kidney Transplant Researcher
Globe Newswire
Vera Therapeutics to Host Business Update Call
Globe Newswire
Vera Therapeutics to Participate in the 42nd Annual Cowen Health Care Conference
Globe Newswire
Vera Therapeutics Announces Closing of Upsized Public Offering of Class A Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
Globe Newswire
Vera Therapeutics Announces Pricing of Upsized Public Offering of Class A Common Stock

Profile

Vera Therapeutics Inc. is a clinical-stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. Vera Therapeutics Inc. is based in SOUTH SAN FRANCISCO, Calif.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2024.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2024 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.